stockrow
Friday 6 November 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024.
- Revenue
- +29.9%
- EPS
- −49.9%
- Free cash flow
- −19.7%
- Total debt
- +1.29%
Quarter to September 2026, against a year earlier
26.39
0.38
+1.46%
Follow CBLL
Alert me
CeriBell, Inc. (CBLL) P/E ratio
CeriBell, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CBLL CeriBell, Inc. | n/m |
| BBNX Beta Bionics, Inc. compare | n/m |
| AHCO AdaptHealth Corp. compare | n/m |
| SIBN SiBone compare | n/m |
| QDEL QuidelOrtho Corporation compare | n/m |
| PRCT PROCEPT BioRobotics Corporation compare | n/m |
| BVS Bioventus Inc. compare | 12.3× |
| IRMD iRadimed Corporation compare | 44.9× |
| IART Integra LifeSciences Holdings Corporation compare | 83.0× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)